

IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL POPULATION AND THE PRISON POPULATION IN MANAUS, AMAZONAS

Isabella da Motta Passos¹; Núria Medeiros Mendonça²

João Victor Magalhães de Souza³

Highlights: (1) COVID-19 delayed tuberculosis diagnosis in the general population. (2) Activescreening reduced tuberculosis cases in prison population. (3) Isoniazid showed highest resistance in both populations.

PRE-PROOF

(as accepted)

This is a preliminary, unedited version of a manuscript that has been accepted for publication in Revista Contexto & Saúde. As a service to our readers, we are making this initial version of the manuscript available as accepted. The article will still be reviewed, formatted, and approved by the authors before being published in its final form.

<http://dx.doi.org/10.21527/2176-7114.2025.50.15437>

How to cite:

Passos I da M, Mendonça NM, de Souza JVM. Impact of the COVID-19 pandemic on tuberculosis diagnosis in the general population and those deprived of liberty in Manaus, Amazonas. Rev. Contexto & Saúde, 2025;25(50): e15437

¹ Secretaria Municipal de Saúde, Manaus/AM, Brasil. Universidade do Estado do Amazonas – UEA. Manaus/AM, Brasil. <https://orcid.org/0000-0003-4875-5042>

² Universidade do Estado do Amazonas – UEA. Manaus/AM, Brasil. <https://orcid.org/0009-0000-5842-3565>

³ Universidade do Estado do Amazonas – UEA. Manaus/AM, Brasil. <https://orcid.org/0009-0003-7850-9544>

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

ABSTRACT

Introduction: During the pandemic, health services were restructured to meet the demand from COVID-19 cases, which led to the neglect of other diseases, including tuberculosis (TB).

Objective: Assess whether there was a change in the number of TB cases identified using the rapid molecular test for tuberculosis and whether there was an increase in resistance to antituberculosis drugs after the pandemic, both in the general population and the prison population. **Methodology:** Individuals who underwent molecular rapid testing for tuberculosis (MRT-TB) and sensitivity tests to anti-TB drugs were evaluated at the Northern District Municipal Laboratory, during the period from January 2018 to December 2022. **Results:** We included 12,208 (81.7%) individuals from the general population and 2,731 (18.3%) from the prison population (PP) of the city of Manaus. The initial year of the pandemic, 2020, had the highest percentage of positive tests (20.6%, n=205) in the general population. This trend continued in the following years, being equal to 12.5% (n=347) and 12.9% (n=392), in 2021 and 2022, respectively. However, in the PP, the years with the highest rates of positive exams were 2018 and 2019, with 13.1% (n=55) and 20.5% (n=50) respectively, with a significant reduction in the percentage of positive exams in later years. Resistance to the drug Isoniazid was the most frequent resistance found in both the general population and the prison population, but without a significant increase. **Conclusion:** The COVID-19 pandemic negatively influenced the control of tuberculosis, increasing the number of cases of this disease in the general population, and it is necessary to improve health policies to control and reduce cases of this disease.

Keywords: Social isolation, COVID-19, Pulmonary tuberculosis, Drug resistance

INTRODUCTION

Tuberculosis (TB) is an infectious disease transmitted by the bacillus *Mycobacterium tuberculosis* (MTb) and, until 2019, was one of the main causes of death due to infectious disease in the world.¹ The state of Amazonas, especially the capital Manaus, has the highest number of TB cases in Brazil, with 84.1 cases per 100,000 inhabitants, and continues to be a major challenge for health authorities.²

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

As of 2020, with the spread of the COVID-19 pandemic across several countries, the causative virus, known as SARS-CoV2, emerged as the leading cause of death in the world. The pandemic brought about significant changes in people's lives. One of them was the adoption of social distancing measures, which lead to families staying at home for long periods, with the aim of reducing the spread of the COVID-19 virus.³ In the context of TB in the city of Manaus, this recommendation may have facilitated transmission by individuals with bacilliferous TB in isolation with other people/family members. Added to this was the difficulty in accessing TB diagnosis and treatment in health facilities, due to the fact that they were focused on coping with the COVID-19 pandemic.^{4,5}

Another relevant aspect that the pandemic brought was the increased use of various antibiotics during COVID-19 infections, both by medical prescribers and by the general population, through self-medication, the latter often being stimulated by fake news that was spread on the internet.^{6,7} The indiscriminate use of these medications, such as antibiotics and immunosuppressants, may possibly have influenced the virulence of MTb, making it more resistant.⁸⁻¹⁰

One population that is particularly vulnerable to the transmission of infectious diseases, in particular TB, is the prison population (PP). This vulnerability can be explained due to infrastructure issues, such as overcrowding in cells and inadequate ventilation, as well as malnutrition, illiteracy and smoking.^{11,12}

Given the above, this study aims to evaluate the impact of the COVID-19 pandemic on the increase in the number of TB cases in the general population and in the prison population in Manaus, as well as observe whether there was an increase after the pandemic in resistance to first-line drugs used in TB treatment.

METHODOLOGY

This is a retrospective, observational, descriptive and analytical study of sputum exam results of patients with suspected TB. Individuals from the general population and the PP, who entered

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

the Bacteriology sector of the North District Municipal Laboratory in Manaus, with a medical request for laboratory diagnosis of TB, during the period from January 2018 to December 2022 were evaluated.

The North District Municipal Laboratory is responsible for conducting laboratory tests of clinical samples of the entire northern sector of Manaus, one of the most populous areas of the city. Patients are treated in the basic health units, by doctors or nurses, and are sent with the request to perform the tests in the laboratory. In addition to the basic health units, the laboratory receives biological samples, including sputum, from five prison units, located at Km 8 on the BR 174 highway.

All the sputum samples from individuals over 18 years of age, of either sex, were selected. Individuals with incomplete or antagonistic registration data were excluded.

The epidemiological characteristics (sex, age and new case/retreatment) and the results of the molecular rapid test for tuberculosis (MRT-TB) were collected using SoftLab, which is the software used by the laboratory network in Manaus. The results of the sensitivity test, which is performed by LACEN-AM, were collected using the GAL program (laboratory environment manager), which is a program of the Brazilian Ministry of Health, used nationally for routine laboratory monitoring.

The MRT-TB was used for the detection of the IS1081-IS6110 gene of the MTb bacillus using the Gene Xpert system (Cepheid, USA), which performs a polymerase chain reaction (PCR) technique in real time. Results indicative of “traces” were not included in the study and were designated as indeterminate. The evaluation of drug resistance was evaluated via two methodologies: 1) detection of mutations of the *rpoB* gene, which indicate resistance to Rifampicin, which is also done via MRT-TB; 2) results of sensitivity tests performed when MTb culture growth occurs, which indicates the sensitivity to the four first-line drugs used in the treatment of tuberculosis (Rifampicin, Isoniazid, Streptomycin and Ethambutol).¹³

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

Analyses of results and individualized statistics of the general population and the prison population were carried out. Analysis of descriptive and exploratory data was performed using IBM SPSS Statistics (version 22.0). To verify the normality of the data in both groups, the Shapiro-Wilk test was used. For data without normal distribution, the Mann-Whitney test was used. The relationships between the diagnosis obtained through the MRT-TB and the year of occurrence were verified using Pearson's chi-square test, as well as the presence of resistance to anti-tuberculosis drugs in both populations. The significance level of 5% was used.

The study complied with the recommendations of Resolution 466/2012 of the National Health Council, which regulates human research in Brazil. The study plan was submitted to the Ethics Committee of the Amazonas State University, through the Plataforma Brasil, and approved under certificate of presentation for ethical assessment (CAAE) No. 56619422.7.0000.5016, opinion No. 5,285,424.

RESULTS

Characterization of the study populations

A total of 14,939 tests were included, these being 12,208 (81.7%) individuals from the general population and 2,731 (18.3%) individuals from the PP of the city of Manaus, capital of the state of Amazonas, which were carried out between the years 2018 and 2022. In 2020, there was the lowest inclusion of individuals for testing for TB in the general population, corresponding to the initial year of the pandemic. In the PP, the lowest inclusion of individuals was in 2019, before the pandemic period. After this decline in 2019 and 2020, the number of examinations in the two populations continued to increase in the subsequent years (Table 1).

In the general population, of the 12,208 examinations, 6,245 (51.2%) were for females and 5,963 (48.8%) were for males. In the prison population, of the 2,731 exams, only 73 (2.7%) refer to females, while 2,658 (97.3%) refer to males (Table 1).

As for the age group, in the general population, the highest frequencies are in the age groups 19 to 29 and 40 to 49, which correspond respectively to 2,686 (22.0%) and 2,312 (18.9%) and

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

make up 40.9% of this population. In the PP, 1,617 (59.2%) tests were performed on individuals aged between 19 and 29 (Table 1).

Regarding the type of case, for the general population, 11,290 (92.5%) are new cases, while in the prison population, 2,566 (94.0%) refer to the same group of cases (Table 1).

Table 1 – Frequency of examinations per year and the epidemiological characteristics of the general population and the prison population

CHARACTERISTIC	General population		Prison population	
	n (12,208)	%	n (2,731)	%
Year				
2018	2,536	20.8	421	15.4
2019	2,854	23.4	244	8.9
2020	996	8.2	581	21.3
2021	2,775	22.7	715	26.2
2022	3,047	25.0	770	28.2
Sex				
Female	6,245	51.2	73	2.7
Male	5,963	48.8	2,658	97.3
Age group				
19 - 29	2,686	22.0	1,617	59.2
30 - 39	2,077	17.0	811	29.7
40 - 49	2,312	18.9	218	8.0
50 - 59	2,110	17.3	54	2.0
60 - 69	1,788	14.6	28	1.0
70 and over	1,235	10.1	3	0.1
Type of case				
New case	11,290	92.5	2,566	94.0
Retreatment	918	7.5	165	6.0

Source: Elaborated by the authors.


Laboratory profile of detection results from MRT-TB

In the five-year period analyzed, 1,387 (11.4%) MRT-TB tests were positive in the general population, while in the PP, MTb detection occurred in 242 (8.9%) tests.

IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL POPULATION AND THE PRISON POPULATION IN MANAUS, AMAZONAS

In the general population, the initial year of the pandemic (2020) had the highest percentage of positive tests 20.6% (n=205). The percentages of positive tests in the following years (2021 and 2022) continued to be higher than before the pandemic, being equal to 12.5% (n=347) and 12.9% (n=392), respectively, showing that the frequencies of these positive results were significantly higher ($p < 0.0001$; Figure 1A). In contrast, in the PP, the years with the highest rates of positive tests were 2018 and 2019, with 13.1% (n=55) and 20.5% (n=50), respectively, with a significant reduction in the percentage of positive tests in later years ($p < 0.0001$; Figure 1B).

Figure 1 – Number of tests evaluated for the detection of tuberculosis by MRT-TB and positivity rate in the general population (A) and in the prison population (B), before and during the COVID-19 pandemic



Results for detection of resistance to Rifampicin using MRT-TB


Regarding the evaluation of Rifampicin resistance using MRT-TB, in the general population, 43 (3.1%) tests showed resistance. In the PP, 12 (5.0%) tests indicated drug resistance.

It is observed that in the general population there is an increase in the number of tests that indicate resistance over the five years, but this increase is not accompanied by the resistance index and has no statistical significance ($p=0.150$) (Figure 2A).

IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL POPULATION AND THE PRISON POPULATION IN MANAUS, AMAZONAS

In the PP, only in 2021 ($n=6$, 13.3%) was the number of tests indicating resistance to Rifampicin higher than in other years (before and after the COVID-19 pandemic); however, this difference did not show statistical significance ($p=0.098$; Figure 2B).

Figure 2 – Number of MRT-TB test results evaluated for Rifampicin resistance and the resistance index in the general population (A) and in the prison population (B), before and during the COVID-19 pandemic



Test results for sensitivity to antituberculosis drugs

In the general population, the frequency of tests that showed resistance to antituberculosis drugs were: 18 (2.7%) to Rifampicin; 58 (8.8%) to Isoniazid; and 21 (3.3%) to Streptomycin (Table 2). In the PP, the results showed the following frequencies: four (3.8%) for Rifampicin; five (4.8%) for Isoniazid; one (1.0%) for Ethambutol; and four (3.9%) for Streptomycin (Table 3). Therefore, in the two populations studied, Isoniazid represented the majority of cases of resistance.

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

Table 2 – Relationship between resistance to antituberculosis drugs in the general population before and during the COVID-19 pandemic

Drug	Resistant		Sensitive	Total	p*
Rifampicin	n (18)	Resistance index (%)	n (644)	662	
2018	2	1.5	128	130	0.019*
2019	4	11.4	31	35	
2020	5	3.4	142	147	
2021	4	2.2	177	181	
2022	3	1.8	166	169	
Isoniazid	n (58)	Resistance index (%)	n (604)	662	
2018	11	8.5	119	130	0.657
2019	2	5.7	33	35	
2020	10	6.8	137	147	
2021	16	8.8	165	181	
2022	19	11.2	150	169	
Ethambutol	n (0)	Resistance index (%)	n (636)	636	
2018	0	0.0	130	130	NA
2019	0	0.0	35	35	
2020	0	0.0	143	143	
2021	0	0.0	181	181	
2022	0	0.0	147	147	
Streptomycin	n (21)	Resistance index (%)	n (615)	636	
2018	5	3.8	125	130	0.855
2019	0	0,0	35	35	
2020	5	3,5	138	143	
2021	6	3,3	175	181	
2022	5	3,4	142	147	

NA: Not applicable

Source: Elaborated by the authors.

* Significant at $p < 0.05$ (5%)

Pearson's chi-square test

In the general population, the analysis of the results of the sensitivity tests to antituberculosis drugs revealed only the presence of samples resistant to Rifampicin ($p=0.019$). Despite this

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

result, it cannot be said that the total number of cases of resistance to this drug has increased due to the COVID-19 pandemic (Table 2).

As for the PP, according to Table 3, the analysis of cases of resistance to drugs against TB did not reveal significant resistance to any of the drugs ($p>0.05$).

Table 3 – Relationship between resistance to antituberculosis drugs in the prison population before and during the COVID-19 pandemic

Drug	Resistant	Sensitive	Total	p^*
Rifampicin	n (4)	Resistance index (%)	n (100)	104
2018	0	0.0	38	38
2019	0	0.0	6	6
2020	1	3.8	25	26
2021	2	14.3	12	14
2022	1	5.0	19	20
				0.202
Isoniazid	n (5)	Resistance index (%)	n (99)	104
2018	2	5.3	36	38
2019	1	16.7	5	6
2020	1	3.8	25	26
2021	0	0.0	14	14
2022	1	5.0	19	20
				0.623
Ethambutol	n (1)	Resistance index (%)	n (102)	103
2018	0	0.0	38	38
2019	0	0.0	6	6
2020	0	0.0	26	26
2021	0	0.0	14	14
2022	1	5.3	18	19
				0.347
Streptomycin	n (4)	Resistance index (%)	n (99)	103
2018	2	5.3	36	38
2019	0	0,0	6	6
2020	1	3,8	25	26
2021	1	7,1	13	14
2022	0	0,0	19	19
				0.808

NA: Not applicable

Source: Elaborated by the authors

* Significant at $p<0.05$ (5%)

Pearson's chi-square test

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

DISCUSSION

The main finding of the present study was the significant increase in the number of cases of TB detected during the COVID-19 pandemic (in the years 2020, 2021, 2022) in the general population. However, this same result was not observed in the PP, for which there was a decrease in the rate of positive TB tests over the years analyzed.

The year 2020, the beginning of the pandemic, was the year with the lowest number of TB tests in the general population, but with the highest positivity rate (20.6%). These data suggest greater selectivity of requests, referring individuals with respiratory symptomatic profiles more compatible with TB. The following years (2021 and 2022) show the “rebound effect”, where there is an increase in the demand for TB tests that was higher than in the years before the pandemic. This same trend is also observed in other Brazilian states (Sergipe, Pernambuco, Paraíba, Mato Grosso do Sul and Maranhão) and in other regions of the world (Southeast Asia, Eastern Mediterranean, Western Pacific and some other countries in the Americas).^{1,2} In addition, mandatory social distancing during COVID-19, the difficulty and decrease in TB health care, increased poverty and poor diet may be other factors that contributed to this increase in the number of TB cases after the pandemic.¹⁴⁻¹⁶

In contrast, the present study shows a decrease in the rate of positive tests over the years in the PP. In 2019, the drop in the number of samples sent to perform the MRT-TB was probably due to the rebellions that occurred in prisons and the change in the management that manages the penitentiary complex.^{17,18} As of 2020, an increase in the number of samples sent to the laboratory is observed; however, the rate of positive tests has decreased. Unlike the general population, for which the demand for tests is mostly spontaneous, in the prison there is an active search for respiratory symptoms, which forces the individual to perform tests for TB. With the onset of the pandemic, this search intensified, leading to an increase in the number of samples being sent for testing in the laboratory. Once TB is detected, this individual is isolated for treatment, which is fundamental for breaking the chain of transmission. Although other studies have observed a decrease in the number of TB cases in the PP, they attribute the decrease in

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

detected cases to probable underreporting in the prison population, which is accompanied by a lack of health policies for the care of detainees.^{2,19,20}

Regarding resistance to the antimicrobials used in the treatment of TB, despite the increase in the number of tests showing resistance to Rifampicin detected by MRT-TB in the general population, there was no significant increase in the resistance index. While, in the PP, no increase in this number of individuals with resistance was observed. When assessing the resistance to first-line antibiotics, Isoniazid was found to be the most resistant drug in the two populations studied. The data in the literature show an increase in Rifampicin resistance after the pandemic, but it is not possible to state that there was an increase in overall resistance because of the COVID-19 pandemic.^{2,21} In these studies, it is possible to note that in the year 2020 there is a decrease in cases of resistance and that in later years the cases are close to the years before the pandemic. In 2019, we observed a decrease in drug sensitivity tests, due to the lack of inputs for culture, which may have compromised the quality of the data.

It is important to emphasize that both the WHO and the Brazilian Ministry of Health have dedicated efforts and investments to fill this gap caused by the pandemic.²²⁻²³ In Brazil, the increase in the number of individuals tested, the expansion of preventive treatment, the strengthening of the laboratory network and the inclusion of new technologies that allow shorter treatment times are part of actions aimed at reducing TB cases by 2030.²³⁻²⁴

FINAL REMARKS

The COVID-19 pandemic had a significant impact on tuberculosis cases worldwide, exacerbating already existing challenges in diagnosing and treating this disease. The focus of health resources on dealing with the coronavirus, coupled with social distancing measures and disruptions in health services, led to a decrease in demand for the diagnosis and treatment of tuberculosis.^{15,16,25} The results obtained in the present study demonstrate an increase in the number of TB cases in the general population, despite a decrease in cases in the PP, after the onset of the COVID-19 pandemic. In this context, it is extremely important to intensify the active search for respiratory symptomatic individuals for early detection of cases, develop

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

public policies that increase surveillance for this disease, and implement effective prevention strategies in an attempt to reduce the impact that the pandemic caused, thereby preventing the number of new cases and, consequently, deaths from tuberculosis from increasing even more.

ACKNOWLEDGMENTS

The authors would like to thank Secretaria Municipal de Saúde de Manaus (SEMSA) and Laboratório Central (LACEN-AM) for the provision and use of laboratory data, as well as the Universidade do Estado do Amazonas (UEA) and the Escola de Saúde Pública de Manaus (ESAP) for supporting and encouraging the research.

FUNDING

This study was developed with the support of the Governo do Estado do Amazonas via the Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) and the Universidade do Estado do Amazonas. Call No. 01/2022 – Programa de Apoio à Iniciação Científica do Amazonas (PAIC/ESAP/SEMSA).

REFERENCES:

1. World Health Organization. Global Tuberculosis Report 2023 [Internet]. WHO. 2023 [cited 17 Dec. 2023]. Available at: https://reliefweb.int/report/world/global-tuberculosis-report2023?gad_source=1&gclid=CjwKCAiA1fqrBhA1EiwAMU5m_xft3WOAl2ugT7HdOGyE2cTZohyZOXHbFe7zJzVFUMAfZ8c7RdekxQCccQAvD_BwE.
2. Secretaria de Vigilância em Saúde e Ambiente. Boletim epidemiológico de Tuberculose 2023 [Internet]. GOV.BR. www.gov.br/saude: Ministério da Saúde; Mar 2023 [cited 17 Dec. 2023]. Available at: <https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2023/boletim-epidemiologico-de-tuberculose-numero-especial-mar.2023/view>

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

3. Ministério da Saúde [Conselho Nacional de Saúde]. RECOMENDAÇÃO No 036/2020 [Internet]. DF, Brasília: GV-CNS. Mar 2023 [cited 17 Dec. 2023]. Available at: <https://conselho.saude.gov.br/recomendacoes-cns/recomendacoes-2020?start=40>
4. Nascimento BC, Mesquita CR, Cardoso SRO, Silva VS da. Os impactos da pandemia da COVID-19 no diagnóstico e tratamento da tuberculose. Revista Eletrônica Acervo Saúde [Internet]. 2023 Aug 24 [cited 17 Dec. 2023];23(8):e13033. Available at: <https://acervomais.com.br/index.php/saude/article/view/13033>
5. Hentringer IMB, Ribeiro JADM, Barreto I de JB, Silva AP de SC. Efeito da pandemia da COVID-19 sobre os casos novos de tuberculose no Brasil: uma análise temporal e espacial. O mundo da Saúde [Internet]. 2023 Mar 23 [cited 17 Dec. 2023];47(1). Available at: <https://revistamundodasaude.emnuvens.com.br/mundodasaude/article/view/1513>
6. Melo JRR, Duarte EC, Moraes MV de, Fleck K, Arrais PSD. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cadernos de Saúde Pública [Internet]. 2021;37(4). Available at: <https://www.scielo.org/pdf/csp/2021.v37n4/e00053221/pt>
7. Khoshbakht R, Bonab SM, Hajizadegan H, Nooghabi ET, Ghorbani A, Asgari MM, et al. Comparing Self-Medication and Medical Supervised Treatment before Hospitalization among Patients with COVID-19: A Retrospective Case-Control Study. Journal of Infection and Public Health. Dec 2023 1;16:119–24. Available at: <https://pubmed.ncbi.nlm.nih.gov/37925306/>
8. Silva BPM, Almeida AS, Sérgio MGM, Gatto TC, Carasek VP, Yamamura M. Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance. Rev Bras Enferm. [Internet]. 2023 [cited 17 Dec. 2023];76(Suppl 1):e20220803. Available at: <https://doi.org/10.1590/0034-7167-2022-0803>
9. Silva LOP, Nogueira JMR. "Indiscriminate use of antibiotics during the pandemic: increasing in post-COVID-19 bacterial resistance". Revista Brasileira de Análises Clínicas [Internet]. 2021 [cited 17 Dec. 2023];53(2). Available at: <https://www.rbac.org.br/artigos/uso-indiscriminado-de-antibioticos-durante-pandemia-o-aumento-da-resistencia-bacteriana-pos-COVID-19/>
10. Mbewana Ntshanka NG, Titus AM. Msagati. Trends and Progress on Antibiotic-Resistant Mycobacterium tuberculosis and Genes in relation to Human Immunodeficiency Virus. Canadian Journal of Infectious Diseases & Medical Microbiology. Nov 2023 30;2023:1–19. Available at: <https://www.hindawi.com/journals/cjidmm/2023/6659212/>
11. Moreira TR, Lemos AC, Colodette RM, Gomes AP, Batista RS. Prevalência de tuberculose na população privada de liberdade: revisão sistemática e metanálise. Revista Panamericana de Salud Pública [Internet]. Jan 2019 4 [cited 17 Dec. 2023];43(16):1–9. Available at:

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

<https://iris.paho.org/bitstream/handle/10665.2/49671/v43e162019.pdf?sequence=1&isAllowed=y>

12. Silva CZD. Tuberculose: doença epidêmica na comunidade carcerária - uma revisão literária da saúde pública brasileira. *Brazilian Journal of Health Review* [Internet]. 2023 Apr 7 [cited 17 Dec. 2023];6(4):14392–403. Available at: <https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/61306>

13. Ministério da Saúde. Manual de Recomendações para Diagnóstico Laboratorial de Tuberculose e Micobactérias não Tuberculosas de Interesse em Saúde Pública no Brasil [Internet]. GOV.BR. 2022 [cited 17 Dec. 2023]. Available at: <https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/manual-de-recomendacoes-e-para-diagnostico-laboratorial-de-tuberculose-e-micobacterias-nao-tuberculosas-de-interesse-em-saude-publica-no-brasil.pdf/view>

14. Hino P, Yamamoto T, Tavares G, Bertolozzi M, Taminato M, Lucimara F, et al. Impacto da COVID-19 no controle e reorganização da atenção à tuberculose. *Acta Paul Enferm* [Internet]. 2021 [cited 17 Dec. 2023];34:2115. Available at: <https://www.scielo.br/j/apae/a/7CHK6rszL4RzWRsrYQb4mVn/>

15. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. *The Lancet Respiratory Medicine* [Internet]. Jun 2022 [cited 17 Dec. 2023];10(6):603–22. Available at: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(22\)00092-3/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00092-3/fulltext)

16. Oliveira G, Tolentino A, Fagundes L, Santos A, Santos A, Bandeira R, et al. Impacto da COVID-19 na Morbimortalidade na Tuberculose no Brasil. *Brasil Psych Tech & Health Journal* [Internet]. 2023 [cited 17 Dec. 2023];6(2):18–28. Available at: <https://www.redalyc.org/journal/6880/688074836003/html/>

17. Rylo I. 40 presos são achados mortos dentro de cadeias do Amazonas [Internet]. G1. 2019 [cited 17 Dec. 2023]. Available at: <https://g1.globo.com/am/amazonas/noticia/2019/05/27/mais-presos-sao-achados-mortos-dentro-de-cadeias-em-manaus-15-morreram-neste-domingo.ghtml>

18. Marques P. Após massacre de detentos, Umanizzare deixa gestão de presídio no Amazonas [Internet]. G1. 2019 [cited 17 Dec. 2023]. Available at: <https://g1.globo.com/am/amazonas/noticia/2019/07/13/umanizzare-deixa-gestao-do-compaj-no-am-nova-empresa-assume-apos-governo-dispensar-licitacao-de-r-3209-milhoes.ghtml>

19. Nascimento DRD, Serpa SF, Bezerra-Santos M, Carmo RFD, Brito RJVCD, Gomes OV, et al. The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020–2021. *The International Journal of Tuberculosis and Lung Disease* [Internet]. 2023 Sep 1 [cited 17 Dec. 2023];27(9):688–93. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443780/>

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

20. Caldas ACL, Campos AF de PE, Silva GF da, Moraes L de F da C, Moraes LS, Carmo LKC do, Andrade LRF, Almeida MFBS, Araújo RCM de. Análise dos casos de tuberculose em pessoas privadas de liberdade no sistema carcerário brasileiro. Rev. Foco [Internet]. 2024 Mar. 28 [cited 2024 Jun. 6];17(3):e4767. Available from: <https://ojs.focopublicacoes.com.br/foco/article/view/4767>
21. Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sergio Arouca, Centro de Referência Professor Hélio Fraga. Boletim epidemiológico da Tuberculose Drogarresistente [Internet]. FIOCRUZ/ENSP. 2022 Mar [cited 17 Dec. 2023]. Available at: <https://www.arca.fiocruz.br/handle/icict/51964>
22. PAHO/WHO | Pan American Health Organization [Internet]. A resposta à tuberculose se recupera da pandemia, mas requer esforços acelerados para alcançar as novas metas; 7 Nov 2023 [citado 6 maio 2024]. Available at: <https://www.paho.org/pt/noticias/7-11-2023-resposta-tuberculose-se-recupera-da-pandemia-mas-requer-esforcos-acelerados-para#:~:text=A%20OMS%20informa%20que%20os,infecciosa%20do%20mundo%20em%202022>.
23. Ministério da Saúde [Internet]. Tuberculose tem cura; conheça a atuação do Ministério da Saúde para eliminar a doença no Brasil; 24 Mar 2023 [citado 6 May 2024]. Available at: <https://www.gov.br/saude/pt-br/assuntos/noticias/2023/marco/tuberculose-tem-cura-conheca-a-atuacao-do-ministerio-da-saude-para-eliminar-a-doenca-no-brasil>
24. Ministério da Saúde [Internet]. Ministério da Saúde lança campanha de combate à tuberculose e reforça ações para eliminação da doença no Brasil; 24 Mar 2023 [citado 6 May 2024]. Available at: <https://www.gov.br/saude/pt-br/assuntos/noticias/2023/marco/ministerio-da-saude-lanca-campanha-de-combate-a-tuberculose-e-reforca-aco-es-para-eliminacao-da-doenca-no-brasil>
25. Diniz DS, Teixeira ED, Almeida WG, Souza MS. Covid-19 e Doenças Negligenciadas ante as desigualdades no Brasil: uma questão de desenvolvimento sustentável. Saude em Debate [Internet]. Dec 2021 [citado 6 May 2024];45(spe2):43-55. Available at: <https://doi.org/10.1590/0103-11042021e203>

Submitted: December 21, 2023

Accepted: August 29, 2024

Published: April 14, 2025

**IMPACT OF THE COVID-19 PANDEMIC ON TUBERCULOSIS DIAGNOSIS IN THE GENERAL
POPULATION AND THE PRISON POPULATION
IN MANAUS, AMAZONAS**

Author contributions:

Isabella da Motta Passos: Conceptualization, Investigation, Data curation, Methodology, Project administration, Supervision, Validation, Writing – original draft.

Núria Medeiros Mendonça: Data curation, Investigation, Methodology, Visualization, Writing – review & editing.

João Victor Magalhães de Souza: Data curation, Investigation, Methodology, Visualization, Writing – review & editing.

All the authors approved the final version of the text.

Conflicts of interest: There are no conflicts of interest.

Corresponding author:

Isabella da Motta Passos

Universidade do Estado do Amazonas

Escola Superior de Ciências da Saúde

Laboratório de Imunologia

Av. Carvalho Leal, 1777, Cachoeirinha, Manaus/AM), Brasil. CEP 69065-001.

ipassos@uea.edu.br

Editor: Christiane de Fátima Colet. PhD

Editor-in-chief: Adriane Cristina Bernat Kolankiewicz. PhD

This is an open access article distributed under the terms of the Creative Commons license.

